FindTrial
Sign In

Intrathecal bupivacaine with morphine versus bupivacaine with buprenorphine for spinal anesthesia for cancer cervix

Comparative study of Intrathecal hyperbaric bupivacaine with Morphine Versus intrathecal hyperbaric bupivacaine with Buprenorphine in Brachytherapy for Ca cervix - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064527
Enrollment
74
Registered
2024-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Intrathecal hyperbaric bupivacaine with Morphine Versus intrathecal hyperbaric bupivacaine with Buprenorphine in Brachytherapy for Ca cervix: inj hyperbaric bupivacaine (2ml) with morph
200 mcg) versus intrathecal hyperbaric bupivacaine (2 ml) with buprenorphine (0.2ml
60mcg) Control Intervention1: Intrathecal hyperbaric bupivacaine with Morphine Versus intrathecal hyperbaric bupivacaine with Buprenorphine in Brachytherapy for Ca cervix: compare the duration of need

Sponsors

SHREE KRISHNA HOSPITAL BHAIKAKA UNIVERSITY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the patients undergoing Brachytherapy for cervical cancer

Exclusion criteria

Exclusion criteria: 1. Patients refusing in take part in the study. 2. 2. Patients who are allergic to amide local anaesthetic drugs 3. Patients who have contraindication for spinal anaesthesia such asinfection at the site of injection, bleeding or coagulation abnormality, increased intracranial pressure , spinal deformities.

Design outcomes

Primary

MeasureTime frame
time when patient has ambulation and demands rescue analgesiaTimepoint: 0 min, 15 min, 30 min, 45 min, 60 min, then every 30 min till 720 min—

Secondary

MeasureTime frame
To study the effects of intrathecal Buprenorphine on intraoperative hemodynamics, side effects (Bradycardia, hypotension, respiratory depressions, pruritus, nausea, vomitingTimepoint: 0 min, 15 min, 30 min, 45 min, 60 min, then every 30 min till 720 min—

Countries

India

Contacts

Public ContactSARDHARA DARVIN RAMESHBHAI

H M PATEL CENTER FOR MEDICAL CARE AND EDUCATION

madhavic@charutarhealth.org9427084963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026